Les autorités de santé ont décidé de changer le calendrier des vaccinations. Désormais, les bébés auront moins de piqûres.
La France va décider de rejoindre le modèle vaccinal qui existe chez ses voisins suédois, danois ou finlandais. Il prévoit notamment moins de vaccins chez les enfants lors des premières années de la vie mais la vaccination est obligatoire (diphtérie-tétanos-poliomyélite) pour garantir une bonne couverture sanitaire.
"The Global Advisory Committee on Vaccine Safety (GACVS) was established in 1999 to respond promptly, efficiently, and with scientific rigour to vaccine safety issues of potential global importance.
The Committee provides independent, authoritative, scientific advice to WHO on vaccine safety issues of global or regional concern with the potential to affect in the short or long term national immunization programmes."
If you haven't yet seen Captain Phillips, I won't spoil it. Since it's a biopic based on events recently in the news, though, I think it's fair to mention that the U.S. Navy deployed a destroyer and a SEAL team to thwart the abduction of a middle-aged guy from Massachusetts.
GlaxoSmithKline (GSK) has unveiled results of a Phase III clinical trial of its human papillomavirus (HPV) vaccine Cervarix for the prevention of cervical cancer in 9-14 year old girls.
Around 1,447 patients aged 9-25 years from across five countries were given Cervarix in the HPV-070 trial, which showed that two doses of the vaccine in girls aged 9-14 years provide an immunogenicity matching the currently licensed three-dose schedule in 15-25 year olds.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted unanimously to approve updated adult, child/adolescent and catch-up immunization schedules for the coming year during its Oct. 23-24 meeting(www.cdc.gov) in Atlanta. Committee members also discussed a number of other vaccine-related issues of interest to family physicians.
Seth Berkley, directeur de l’Alliance GAVI à Genève, montre comment le Rwanda est parvenu à vacciner 93% des adolescentes contre le papillomavirus humain, score que les pays riches sont loin d’atteindre.
Just one dose of a human papillomavirus (HPV) vaccine may be enough to provide long-term protection against cervical cancer in women, a new study suggests.
The HPV vaccine is currently recommended as a three-dose series, but doctors have found it difficult to finish out the series for many girls.
However, the researchers discovered active human papillomavirus antibodies in Costa Rican women four years after they had received only one dose of Cervarix, a vaccine that protects against two HPV strains.
Health activists have expressed shock over the government’s tie-up with One World Health (OWH), an affiliate of Program for Appropriate Technology in Health (PATH), for a training workshop on crisis management in clinical research for clinical trial professionals organised by the Department of Science and Technology.
One of the world’s leading immunization groups is launching a new program aimed at vaccinating girls in Laos against human papillomavirus, or HPV, to curb rising rates of cervical cancer. The Global Alliance for Vaccines and Immunization (GAVI) said developing countries in South East Asia, such as Laos and Burma, still face major challenges in implementing vaccination programs.
The three-injection vaccination costs about $120 per shot in the United States and is typically given to girls nine to 13 years old.